US20260306631
2026-10-08
Human necessities
A61K40/31
Chimeric receptors composed of homodimeric polypeptides are the focus, with significant applications in tumor immunotherapy, particularly adoptive cell therapy. These receptors enhance immune responses against target antigens by genetically modifying therapeutic immune cells. The patent discusses therapeutic cells expressing these chimeric receptors and outlines methods for treating patients using these modified cells.
The chimeric receptor is a homodimer consisting of two polypeptide monomers, each with three key regions:
These receptors address challenges faced by CAR T cells, particularly in solid tumors, by improving persistence without antigen stimulation and functionality amidst chronic antigen exposure. This is achieved by incorporating cytokines like IL-2, IL-7, IL-15, and IL-21, enhancing antitumor activity while managing safety concerns associated with cytokine activation of bystander cells.
The intracellular signaling regions can activate various pathways, including:
These pathways are crucial for robust immune responses, enabling the engineered cells to combat tumors effectively.
Chimeric receptors can be tailored with specific signaling regions derived from cytokine receptors or receptor tyrosine kinases, such as EGFR or Toll-like receptors. This flexibility allows for the customization of therapeutic cells to target various cancer types, enhancing the efficacy and safety of immunotherapies.